Focus: Celcuity is an oncology-focused diagnostics and precision medicine company specializing in PI3K/mTOR pathway therapies and companion diagnostics for breast cancer and other solid tumors. The company operates from Minneapolis with a focused pipeline of gedatolisib-based combinations in clinical development.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Celcuity offers early-career or specialized clinical/diagnostics professionals a chance to shape a commercial launch in precision oncology, but limited hiring signals and narrow pipeline focus present moderate growth and job security concerns.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
First-to-market PI3K/mTOR dual inhibitor approved for ER+ breast cancer; commercial launch underway with 7+ year LOE runway providing revenue stability.
Help build intelligence for Celcuity
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Celcuity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles